At a glance
- Originator National Institutes of Health (USA)
- Developer National Institutes of Health (USA); SciClone Pharmaceuticals
- Class Small molecules; Xanthines
- Mechanism of Action Adenosine A1 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cystic fibrosis
Most Recent Events
- 18 Nov 1999 Preclinical development for Cystic fibrosis in USA (PO)